Inhibition of Mammalian Glycoprotein YKL-40 \u3cem\u3eIDENTIFICATION OF THE PHYSIOLOGICAL LIGAND\u3c/em\u3e by Kognole, Abhishek A. & Payne, Christina M.
University of Kentucky
UKnowledge
Chemical and Materials Engineering Faculty
Publications Chemical and Materials Engineering
1-4-2017
Inhibition of Mammalian Glycoprotein YKL-40
IDENTIFICATION OF THE PHYSIOLOGICAL
LIGAND
Abhishek A. Kognole
University of Kentucky, abhishek.kognole@uky.edu
Christina M. Payne
University of Kentucky, christy.payne@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/cme_facpub
Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry, Biophysics, and
Structural Biology Commons, Chemical Engineering Commons, Genetics and Genomics
Commons, and the Materials Science and Engineering Commons
This Article is brought to you for free and open access by the Chemical and Materials Engineering at UKnowledge. It has been accepted for inclusion in
Chemical and Materials Engineering Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Kognole, Abhishek A. and Payne, Christina M., "Inhibition of Mammalian Glycoprotein YKL-40 IDENTIFICATION OF THE
PHYSIOLOGICAL LIGAND" (2017). Chemical and Materials Engineering Faculty Publications. 42.
https://uknowledge.uky.edu/cme_facpub/42
Inhibition of Mammalian Glycoprotein YKL-40 IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND
Notes/Citation Information
Published in The Journal of Biological Chemistry, v. 292, no. 7, p. 2624-2636.
This research was originally published in The Journal of Biological Chemistry. Abishek A. Kognole and
Christina M. Payne. Inhibition of Mammalian Glycoprotein YKL-40 IDENTIFICATION OF THE
PHYSIOLOGICAL LIGAND. J. Biol. Chem. 2017; 292:2624-2636. © 2017 by The American Society for
Biochemistry and Molecular Biology. Inc.
The copyright holder has granted the permission for posting the article here.
Digital Object Identifier (DOI)
https://doi.org/10.1074/jbc.M116.764985
This article is available at UKnowledge: https://uknowledge.uky.edu/cme_facpub/42
Inhibition of Mammalian Glycoprotein YKL-40
IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND*□S
Received for publication, October 26, 2016, and in revised form, December 22, 2016 Published, JBC Papers in Press, January 4, 2017, DOI 10.1074/jbc.M116.764985
Abhishek A. Kognole and X Christina M. Payne1
From the Department of Chemical and Materials Engineering, University of Kentucky, Lexington, Kentucky 40506
Edited by Gerald W. Hart
YKL-40 is a mammalian glycoprotein associated with pro-
gression, severity, and prognosis of chronic inflammatory dis-
eases and a multitude of cancers. Despite this well documented
association, identification of the lectins physiological ligand
and, accordingly, biological function has proven experimentally
difficult. YKL-40 has been shown to bind chito-oligosaccha-
rides; however, the production of chitin by the human body has
not yet been documented. Possible alternative ligands include
proteoglycans, polysaccharides, and fibers like collagen, all of
which makeup the extracellular matrix. It is likely that YKL-40 is
interacting with these alternative polysaccharides or proteins
within the body, extending its function to cell biological roles
such as mediating cellular receptors and cell adhesion and
migration. Here, we consider the feasibility of polysaccharides,
including cello-oligosaccharides, hyaluronan, heparan sulfate,
heparin, and chondroitin sulfate, and collagen-like peptides as
physiological ligands for YKL-40. We use molecular dynamics
simulations to resolve the molecular level recognition mecha-
nisms and calculate the free energy of binding the hypothesized
ligands to YKL-40, addressing thermodynamic preference rela-
tive to chito-oligosaccharides. Our results suggest that chito-
hexaose and hyaluronan preferentially bind to YKL-40 over col-
lagen, and hyaluronan is likely the preferred physiological
ligand, because the negatively charged hyaluronan shows
enhanced affinity for YKL-40 over neutral chitohexaose. Colla-
gen binds in two locations at the YKL-40 surface, potentially
related to a role in fibrillar formation. Finally, heparin non-spe-
cifically binds at the YKL-40 surface, as predicted from struc-
tural studies. Overall, YKL-40 likely binds many natural ligands
in vivo, but its concurrence with physical maladies may be
related to associated increases in hyaluronan.
YKL-40, also known as chitinase 3-like 1, is a mammalian
glycoprotein implicated as a biomarker associated with pro-
gression, severity, and prognosis of chronic inflammatory dis-
eases and a multitude of cancers (1– 4). Many different types of
cells including synovial, endothelial, epithelial, smooth muscle,
and tumor cells produce YKL-40 in vivo, likely in response to
environmental cues (5– 8). Speculation as to biological function
of YKL-40 varies from both inhibiting and antagonizing colla-
gen fibril formation as a result of injury or disease (9), as well as
conferring drug resistance and increasing cell migration lead-
ing to progression of cancer (3), and protection from chitin-
containing pathogens (10). Although the association of YKL-40
with physical maladies is well documented, identification of the
physiological ligand of this lectin, and thus biological function,
remains elusive.
Mammalian YKL-40 is classified as a family 18 glycoside
hydrolase based on high homology with this well conserved
class of enzymes in the CAZy database (10 –12). Although sim-
ilar in structure to family 18 glycoside hydrolases, YKL-40 lacks
catalytic activity as a result of substitution of the glutamic acid
and aspartic acid motif typical of catalytically active family 18
hydrolases, rendering YKL-40 a lectin, a non-catalytic sugar-
binding protein. Structural evidence suggests that YKL-40
exhibits at least two functional binding regions (10). The pri-
mary binding cleft has nine binding subsites lined with aro-
matic residues compatible with carbohydrate binding (Fig. 1). A
putative heparin-binding site, located within a surface loop, has
also been suggested (Fig. 1), although in vitro binding affinity
studies have been unable to conclusively demonstrate this (11).
Binding affinity and structural studies reveal that chito-
oligosaccharides are natural substrates (6, 10, 11). In line with
family 18 glycoside hydrolases, YKL-40 uniquely binds short
and long chito-oligomers, indicating preferential site selection
based on affinity (10). Chitohexaose binding has also been pur-
ported to induce conformational changes in YKL-40 (10),
although this has not been observed in all structural studies
(11). Lectin binding niches are widely believed to be “pre-
formed” to the preferred ligand, exhibiting little conforma-
tional change upon binding (13, 14). Despite apparent affinity,
chitin is not a natural biopolymer within mammalian or bacte-
rial cells, and the presence of chitin or chito-oligosaccharides in
mammals is likely related to fungal infection (15). The noted
up-regulation of YKL-40 in response to inflammation lends
credence to the argument that YKL-40 functions as part of the
innate immune response in recognition of self from non-self (6,
16); however, high expression levels of YKL-40 in carcinoma
tissues suggest function beyond the innate immune response
may also exist (17, 18). The extracellular matrix is comprised of
a mesh of proteoglycans (protein-attached glycosaminogly-
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cans), polysaccharides, and fibers including collagen. An alter-
nate theory to the pathogenic protection function is that a
closely related polysaccharide, instead of chitin, plays the role of
the physiological ligand in mediating cellular function (11).
Despite the structural similarity between chito-oligosaccha-
rides and the proteoglycan carbohydrate monomers, little evi-
dence of polysaccharide binding beyond the original structural
studies exists (10, 11). In fact, we are aware of only one other
study focusing on the molecular-level mechanism of carbohy-
drate binding in YKL-40 (19). From a bioinformatics and struc-
tural comparison of YKL-40 to a similar chi-lectin, mammary
gland protein 40 (20), the authors propose an oligosaccharide
binding mechanism that involves tryptophan-mediated gating
of the primary carbohydrate binding site (Fig. 1) (19). However,
in lieu of a dynamics-based investigation, little can be con-
cluded about the binding mechanism of YKL-40 ligands other
than chito-oligosaccharides, and conformational changes rela-
tive to binding are inaccessible. From protein purification tech-
niques, namely heparin-Sepharose chromatography, we also
know that YKL-40 reversibly binds heparin (7, 11, 21); however,
affinity data for this interaction do not exist. Based on the inter-
action with heparin, it is reasonable to hypothesize heparan
sulfate glycosaminoglycans, existing as part of the extracellular
matrix construct, are potential physiological ligands. Visual
inspection of the protein structure suggests that heparan sul-
fate fragments may be easier to accommodate within the car-
bohydrate-binding site than heparin itself (11). It follows that
other structurally similar carbohydrate fragments would bind
with similar affinity in a comparable mechanism.
The association of YKL-40 with ailments such as arthritis,
fibrosis, and joint disease is suggestive of molecular-level inter-
actions with connective tissue and thus collagen (22–26). Moti-
vated by understanding the physiological role of YKL-40 in
connective tissue remodeling and inflammation, Bigg et al. (9)
investigated association of YKL-40 with collagen types I, II, and
III using affinity chromatography to confirm binding to each
type. The authors report YKL-40 specifically binds to all three
collagen types. Additionally, the authors used surface plasmon
resonance to confirm binding to collagen type I. Unfortunately,
the reported affinity constants were inconsistent across exper-
iments as a result of aggregation. Nevertheless, the work clearly
indicates that YKL-40 is capable of binding collagen. This fur-
ther confounds the question of mechanism when considering
physiological ligands, because YKL-40 is capable of binding
both protein and carbohydrates.
Understanding the mechanism and affinity by which YKL-40
binds ligands is crucial to our understanding of its physiological
function. This knowledge will serve as a foundation for future
campaigns toward rational development of a potent antago-
nists enabling cell biological study and addressing YKL-40 as a
therapeutic target. To accomplish this goal, we must describe
the molecular level mechanisms governing the interaction of
YKL-40 with both polysaccharide and collagen-like polypep-
tides and quantitatively evaluate affinity. In this study, we used
classical molecular dynamics (MD)2 simulations to differenti-
ate modes of ligand recognition and specificity. Using free
energy perturbation with replica exchange molecular dynamics
(FEP/-REMD) and umbrella sampling MD, we quantitatively
determined affinities overcoming the experimental difficulties
encountered thus far. As physiological ligands, we considered
several options within both the polysaccharide and proteina-
ceous classes. Below, we provide a brief description of each
carbohydrate ligand considered, as well as justification for con-
sideration of the collagen-like models.
Polysaccharides—We selected polysaccharides for this study
based on their similarity to chito-oligomers, as well as natural
occurrence in mammalian cell walls and/or the extracellular
matrix. The chito-oligomer from structural studies was
included as a control (10, 11). Chitin is a naturally occurring
biopolymer comprised of repeating N-acetyl-D-glucosamine
(GlcNAc) monomeric units connected by -1,4-glycosidic link-
ages (Fig. 2). The central ring of the monomer, a six-membered
pyranose, is common to a number of carbohydrates including
glucose. Given the chemical similarity, as well as the general
presence of glucose in mammalian cells as a form of energy, a
hexameric cello-oligomer was also examined as a potential
physiological ligand, despite its unlikely presence among mam-
malian glycosaminoglycans.
As described above, YKL-40 binds heparin, and thus, likely
also binds heparan sulfate. Heparan sulfate, a less sulfated form
of heparin, is a polysaccharide found in abundance in the extra-
cellular matrix and at the cell surface (27). Heparan sulfate is
constructed from a repeating disaccharide of -D-glucuronic
acid and N-acetyl--D-glucosamine (Fig. 2). Of all the glycos-
aminoglycans, heparan sulfate is the most structurally complex.
At least 24 different combinations of the disaccharide mono-
mer exist, with differences arising as a result of variation in both
isomer and degree of side chain sulfation (28). Additionally, the
heparan sulfate polysaccharide can exhibit both sulfated and
unsulfated domains. Physiologically, the unsulfated disaccha-
ride -D-glucuronic acid (1, 4) N-acetyl--D-glucosamine is the
most prevalent form of heparan sulfate (28). Focusing on the
most relevant physiological ligands, we examined the fully sul-
fated form heparin and the unsulfated form heparan sulfate.
2 The abbreviations used are: MD, molecular dynamics; PMF, potential of
mean force; FEP, free energy perturbation; REMD, replica exchange molec-
ular dynamics; WCA, Weeks-Chandler-Anderson; RMSD, root mean square
deviation; RMSF, root mean square fluctuation; PDB, Protein Data Bank.
FIGURE 1. Surface representation of YKL-40 showing the binding cleft
with a bound hexamer of chitin. Binding sites 2 through 4 are num-
bered. Sites 5, 6, and 7 have also been identified but are not shown. The
putative heparin-binding site is shown in blue.
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Hyaluronan is a particularly interesting glycosaminoglycan
relative to this study, because chito-oligosaccharides are pre-
cursors to hyaluronan synthesis in vivo (29 –31). The structural
relationship of these two molecules is such that binding mech-
anisms may be similar at alternating binding sites. Hyaluronan
is a polysaccharide of a repeating -D-glucuronic acid and
N-acetyl--D-glucosamine disaccharides connected by alter-
nating -1,3- and -1,4-glycosidic linkages (Fig. 2). As with
heparan sulfate, hyaluronan is also a glycosaminoglycan com-
prising the extracellular matrix. At extracellular pH, the car-
boxyl groups of glucuronic acid are fully ionized, giving the
ligand an overall negative charge under typical physiological
conditions (32).
Finally, we consider chondroitin sulfate, which is also a gly-
cosaminoglycan prevalent in mammals. The primary structural
units of chondroitin sulfate are a repeating -D-glucuronic acid
and N-acetyl--D-galactosamine disaccharides connected by
alternating -1,3- and -1,4-glycosidic linkages (Fig. 2). As with
heparan sulfate, chondroitin sulfate exists in variably sulfated
types (33); we have selected the C4 and C6 sulfated variant of
chondroitin sulfate polysaccharide as a model.
Collagen-like Peptide Models—Collagen has also been con-
sidered as a potential physiological ligand based on the noted
affinity and participation of YKL-40 in collagen fibril formation
(9). Collagen, unlike the other potential physiological ligands, is
a macromolecular protein with a triple helix structure. There
are at least 27 distinct types of human collagen, forming a vari-
ety of biological networks, all of which are constructed of a basic
Gly-Xaa-Yaa repeating amino acid sequence (34). Generally,
the unspecified amino acids, Xaa and Yaa, are proline and
hydroxyproline, respectively.
Model collagen peptides have been observed in two different
symmetries: the original Rich and Crick model with 10/3 sym-
metry (10 units in 3 turns) and the 7/2 symmetry of a more
tightly symmetrical triple helix (35–37). On the molecular
scale, collagen type will have relatively little impact on binding
to YKL-40. However, symmetry may have an impact on hydro-
gen bonding in the binding site, and thus, overall affinity, which
will provide unique insight into physiological relevance. To
date, model collagen peptides of a true 10/3 symmetry have not
been reported. Rather, the peptides either have a 7/2 helical
pitch or are somewhat “intermediate” in symmetry leading
some to believe that the 7/2 symmetry is representative of the
true collagen helical structure (38). However, it is not known
how universally true this hypothesis is because the structures of
model peptides capture just a small subsection of the larger
macromolecular structure (39).
With a broad range of possible collagen architectures, we
have selected four representative model collagen peptides
whose structures are both available from crystallographic evi-
dence and span the 10/3 and 7/2 symmetries to the greatest
possible extent. The first collagen peptide considered is that of
the basic collagen peptide model, PDB code 1CAG (40). The
reported 1.9 Å resolution structure exhibits a single Gly to Ala
substitution and 7/2 symmetry overall. Near the substitution
site, the helix relaxes somewhat from 7/2 symmetry, although
not so much as to change overall symmetry. The second colla-
gen model peptide we consider is a variation of the 1CAG pep-
tide, where we reverted the alanine substitution to its native
glycine. Minimization of this structure returns the helix to full
7/2 symmetry; we refer to this peptide as “native 1CAG”
here. The third model represents a segment from type III
homotrimer collagen with approximate 10/3 symmetry in the
middle part of the helix (PDB code 1BKV) (35). This middle
part of the 1BKV model peptide, also referred as the T3–785
peptide, has an imino acid-poor sequence of GITGARGLA.
Our fourth model, 1Q7D, is a triple helical collagen-like peptide
sequence including a hexapeptide Gly-Phe-Hyp-Gly-Glu-Arg
(GFOGER) motif in the middle (41); this motif is not suffi-
ciently long to exhibit 10/3 symmetry, exhibiting, rather, an
intermediate degree of 7/2 helical symmetry. This 1Q7D model
is known to bind the integrin 21-I domain protein (42), and
the GFOGER motif is found in the 1 chain of type I collagen.
Experimental Procedures
Molecular Dynamics Simulations
MD simulations were constructed starting from the chito-
hexaose-bound YKL-40 structure (PDB code 1HJW) deposited
by Houston et al. (10). The apo simulation simply removed the
chito-oligomer from the primary binding cleft. The N-linked
glycan captured in the YKL-40 structure, at Asn60, was included
in system preparation. Because crystal structures of YKL-40
bound to other polysaccharides are not available, we used the
structural similarity of polysaccharides as the basis for model-
ing the remaining polysaccharides in this investigation. In the
FIGURE 2. Monomeric units of the polysaccharides considered as poten-
tial physiological ligands of YKL-40: cellohexaose, chitohexaose, hepa-
ran sulfate, heparin, hyaluronan, and chondroitin sulfate. The chito-oli-
gomer is a polymer of -1,4-linked GlcNAc monomers. Heparan sulfate was
modeled as a -1,4, -1,4-linked chain of GlcA and GlcNAc. Heparin was rep-
resented as the -1,4, -1,4-linked oligomer of GlcA and GlcNS. Hyaluronan
and chondroitin sulfate are -1,3, -1,4-linked oligomers; the former consists
of GlcA and GlcNAc, and the latter consists of GlcA and GalNAc. GlcA, -D-
glucuronic acid; IdoA, -D-iduronic acid; GlcNS, N-sulfo--D-glucosamine; Gal-
NAc, N-acetyl--D-galactosamine.
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case of cellohexaose, hyaluronan, heparan sulfate, heparin, and
chondroitin sulfate, we located the central ring atoms of the
ligand backbone in the same location as that of the original
chitohexaose. Appropriate pyranose side chains and glycosidic
linkages (Fig. 2) were added using CHARMM internal coordi-
nate tables to construct the remainder of the sugar residue (43).
All polysaccharides were described using the CHARMM36 car-
bohydrate force field (44 – 46). The missing force-field param-
eters for N-sulfated glucosamine (supplemental Fig. S1) in hep-
arin were developed using the force-field Toolkit plugin for
VMD (47, 48). Details of this parameterization and output
parameters (supplemental Table S2) are reported in the supple-
mental materials.
Construction of the collagen-bound YKL-40 models re-
quired docking calculations to appropriately position the
ligand. The collagen peptides are significantly larger than any of
the carbohydrate ligands; thus, it is unlikely that a collagen mol-
ecule occupies the primary YKL-40 binding site in the same
manner as chito-oligomer. Standard affinity-based docking cal-
culations, such as the ones performed in AutoDock, are not
feasible for determination of an initial collagen-binding domain
given the size and flexibility of the triple helix structures.
Rather, the collagen peptides were docked on the basis of
molecular shape complementarity using the online web server
PatchDock Beta version 1.3 (49, 50). In the case of each of the
four collagen-like model peptides, PatchDock predicted two
potential occupancies along the surface of YKL-40, site A and
site B. Binding site A corresponds to the primary carbohydrate-
binding domain of YKL-40; however, the collagen ligand was
not as deeply entrenched in the cleft as chitohexaose. Binding
site B is located on the opposite side of YKL-40 from the pri-
mary binding cleft. Thus, for each collagen-like peptide, two
MD simulations were constructed representing the two poten-
tial binding sites. Fig. 3 illustrates the results of the docking with
predicted collagen binding sites A and B for the 1Q7D collagen-
like model peptide.
The constructed protein-ligand systems were minimized in
vacuum and subsequently solvated with water and sodium ions.
Using CHARMM (43), the solvated systems were extensively
minimized and heated to 300 K for 20 ps, which was followed by
MD simulation for 100 ps in the NPT ensemble. The coordi-
nates following density equilibration were used as a starting
point for 250 ns of MD simulation in the NVT ensemble at
300 K using NAMD (51). Explicit procedural details are pro-
vided in the supplemental materials.
Free Energy Calculations
FEP/-REMD—Free energy perturbation with Hamiltonian
replica exchange molecular dynamics (FEP/-REMD) was used
to calculate the absolute free energy of binding the polysac-
charide ligands to YKL-40 (52, 53). This protocol uses Ham-
iltonian replica exchange as a means of improving the Boltz-
mann sampling of free energy perturbation calculations. The
parallel/parallel replica exchange MD algorithm in NAMD
was implemented as recently described (51, 54). The free
energy calculations performed using this approach were
accomplished through two separate sets of free energy cal-
culations following the thermodynamic cycle illustrated in
supplemental Fig. S2. To obtain each binding free energy,
G, the bound carbohydrate ligand was first decoupled from
the solvated proteincarbohydrate complex to determine G1.
The second calculation entailed decoupling the solvated oligo-
saccharide from solution into vacuum to obtain G2. The dif-
ference between the two values, G2  G1, gives the absolute
free energy of binding the given ligand to YKL-40.
In each free energy calculation, five separate terms contrib-
ute to the potential energy of the system: the non-interacting
ligand potential energy, repulsive and dispersive contributions
to the Lennard-Jones potential, electrostatic contributions, and
the restraining potential. In each calculation, the ligand was
decoupled from the system by thermodynamic coupling
parameters controlling the non-bonded interaction of the
ligand with the environment. The parameters decoupled the
ligand in a four-stage process, wherein the coupling parameters
defined replicas that were exchanged along the length of the
alchemical pathway. This decoupling has been described in
detail previously (54) and is also reported in the supplemental
materials. A total of 128 FEP replicas were used, and a conven-
tional Metropolis Monte Carlo exchange criterion governed
the swaps throughout the replica exchange process (53). The
free energy of binding was determined from 20 consecutive,
0.1-ns simulations of each corresponding system, where the
first 1 ns of data were discarded as equilibration. One standard
deviation of the last 1 ns of simulation data were used to obtain
an estimate of error. Additional details about these calculations
are described in the supplemental materials.
FIGURE 3. Molecular shape complementarity docking calculations predict collagen-like peptides will bind to YKL-40 in two possible orientations. a,
the front view of YKL-40 (gray surface) with collagen docked in site A (green stick). b, the back view where collagen is docked in site B (cyan stick). c, top view of
YKL-40 illustrating relative positions of binding sites. The putative heparin-binding subsite is shown in blue surface to aid in visualization of relative orientation
of the proteinprotein complexes. This particular figure shows the integrin-binding collagen peptide, 1Q7D (41), in the predicted binding sites along the surface
of YKL-40; similar docking was carried out for other collagen models.
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Umbrella Sampling—Convergence challenges make FEP/-
REMD inappropriate for determining the binding free energy
of the much larger and more flexible collagen-like model pep-
tides. Thus, umbrella sampling was used to determine the work
required to detach the collagen ligands from the shallow clefts
of YKL-40. Over the entire reaction coordinate, this value
equates to binding affinity, enabling relative comparison of col-
lagen peptide affinity. The MD umbrella sampling simulations
used a native contacts-based reaction coordinate analogous to
that defined by Sheinerman and Brooks (55) and as imple-
mented in recent cellulose decrystallization studies (56, 57).
Here, a native contact was defined as a YKL-40 protein residue
within 12 Å of a collagen peptide residue; distance was defined
by center of geometry of a given residue. The cutoff distance
was selected to be larger than the non-bonded cutoff distance,
ensuring that the collagen ligand was no longer interacting with
YKL-40. Additionally, the water boxes of the collagen-YKL-40
systems were made bigger to accommodate the required sepa-
ration distance.
The change in free energy was determined as a function of
the reaction coordinate, , formulated as the weighted sum of
the states of the native contacts. The initial coordinates of the
bound systems were selected from 250-ns equilibrated snap-
shots. The initial number of native contacts and their weights
were calculated from these snapshots. An initial reaction coor-
dinate of 0 (normalized) corresponds to this initial condition,
and a final reaction coordinate of 1 corresponds to all of the
native contacts being outside the 12-Å cutoff (i.e. the ligand is
decoupled and freely sampling the bulk). The reaction coordi-
nate was divided into 20 windows evenly spaced along the reac-
tion coordinate, and each window was sampled for 5 ns, where
the reaction coordinate was maintained at the specified value
using a harmonic biasing force with the force constant of 41,840
kJ/mol. The potentials of mean force profiles were calculated
using the weighted histogram analysis method (WHAM soft-
ware), and error analysis was performed using bootstrapping.
A detailed listing of all the simulations and free energy calcula-
tions performed as part of the objectives of this study is pro-
vided in supplemental Table S1.
Results and Discussion
Protein-Polysaccharide Binding in YKL-40 —MD simulation
suggests that of the six polysaccharide oligomers investigated,
only three bind in a stable fashion in the primary carbohydrate
binding site of YKL-40. The three potential polysaccharide
physiological ligands at this site include chitohexaose, cello-
hexaose, and hyaluronan. In the section that follows, we will
describe the dynamics of chitohexaose, cellohexaose, and hya-
luronan binding to YKL-40. The remaining three ligands—
heparin, heparan sulfate, and chondroitin sulfate—were dis-
lodged from the binding site over the course of MD simulations.
The -1,4-glycosidic linkages in heparin and heparan sulfate,
instead of -1,4, modifies the relative orientation of disaccha-
ride monomers from that of the chito-oligosaccharide. The
NMR solution structure of heparin (PDB code 1HPN) shows
that the relaxed conformation is semi-helical (59), which can-
not be feasibly accommodated in the conserved, narrow carbo-
hydrate binding site of YKL-40. Heparan sulfate suffers from
similar steric constraints posed by the relaxation driving force.
The bulky sulfated side chains of heparin introduce further
steric hindrance and, in the case of heparin and chondroitin
sulfate, unfavorably strong electrostatic interactions resulting
from negatively charged moieties inconveniently located along
the cleft (i.e. without a co-located, oppositely charged protein
residue) eject the ligands from the cleft.
In the cases of heparin, heparan sulfate, and chondroitin sul-
fate, the ligands quickly “relax” from the initial wide V-shaped
conformation as they are expelled from the cleft by charge- and
steric-based effects. Relaxation of the sugar from the initial
binding pose is sufficient to initiate loss of critical non-bonded
interactions along with a subsequent reduction in affinity (Fig.
4). Within 25 ns, heparin, heparan sulfate, and chondroitin sul-
fate were expelled from the cleft into bulk solution. Each of the
three ligands capable of binding with the primary binding cleft
maintained the 1 boat conformation over the entire simula-
tion. Chitohexaose and cellohexaose remained in the binding
cleft over the entire 250-ns MD simulation while maintaining
the initial wide V shape. Hyaluronan developed a sharp V shape
within a few nanoseconds and maintained this conformation
within the binding cleft for the remainder of the simulation
(supplemental Fig. S6); this is primarily due to variation in gly-
cosidic linkage, where hyaluronan exhibits a -1,3-linkage
within the monomer instead of the -1,4-linkage of cello- and
chitohexaose. Also, comparison of the equilibrated chito-
hexaose- and hyaluronan-bound structures disabuses one of
FIGURE 4. Relaxation of the polysaccharide ligands in the primary binding cleft of YKL-40. Each ligand is shown after a 100-ps equilibration in a thick stick
representation. For comparison, the chito-oligomer, in its equilibrated conformation, is shown in thin green lines behind each oligosaccharide. The YKL-40
protein has been aligned such that each oligosaccharide is oriented in the same manner; although YKL-40 is not shown for visual clarity. Heparan sulfate,
heparin, and chondroitin sulfate relax significantly from the initial distorted conformation.
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the notion that similar binding mechanisms exist at alternate
binding sites, because only the 1 site pyranose appears to
maintain similar side chain orientation.
The native distorted conformation is characteristic of glyco-
side hydrolase pyranose binding behavior in the 1 site (Fig. 4)
(60). In solution, polysaccharide pyranose moieties adopt the
energetically favorable chair conformation (61); however, when
bound to an enzyme, the active sites of catalytically active gly-
coside hydrolases distort the pyranose ring in the 1 binding
subsite into a less energetically favorable conformation, such as
a boat or skew conformation (62– 65), priming the substrate for
hydrolytic cleavage. Interestingly, the chitohexaose ligand
bound in the primary binding site of YKL-40 exhibits a boat
conformation despite not being catalytically active (10). This
suggests that the sugar distortion in the 1 binding site con-
tributes to ligand binding as well as catalysis, because there is no
evolutionary requirement to overcome an activation energy
barrier in catalytically inactive lectins. A recent study of a ho-
mologous chitinase suggested that 1 pyranose relaxation
reduces binding affinity and affords the ligand more flexibility
and entropic freedom (66), which is consistent with our find-
ings from the 250-ns MD here.
Putative Heparin-binding Site—Despite the fact that the hep-
arin oligomer could not be accommodated by the YKL-40 bind-
ing cleft, MD simulations do suggest that the oligomer interacts
with the surface of YKL-40 at a putative heparin-binding site
(Fig. 1). After ejection from the primary binding site, the oli-
gomer spontaneously binds to the YKL-40 heparin-binding site
(supplemental Movie S1). To address the significance of this
unanticipated event, we performed three additional indepen-
dent MD simulations of the YKL-40/heparin system: one with a
new random number seed, although in the same configuration,
and two additional simulations with the ligand randomly placed
in solution (supplemental Movie S2). In each case, the heparin
oligomers were capable of finding and binding to a group
of charged residues at the surface of YKL-40 (Fig. 5); these
were the basic residues of a putative heparin-binding site,
GRRDKQH, at positions 143–149. Interestingly, this domain
follows a consensus protein sequence, XBBXBX (where B is a
basic residue and X is any non-basic amino acid), that is noted
for its ability to recognize polyanions like heparin (67). In all
four cases, heparin recognized the binding site within 25 ns of
MD simulation (Fig. 5), occasionally visiting other moderately
basic surface locations before localizing around the GRRDKQH
motif. The strong electrostatic interaction arose from the
dynamic formation of salt bridges between either the sulfate or
the carboxyl groups of the heparin oligosaccharide and the side
chains of the basic amino acids (supplemental Table S3). Lys155
and Lys193 also exhibit large, favorable interactions with hepa-
rin, interacting with the opposite end of the polysaccharide
ligand as it binds at the surface. Coupled with experimental
observation of heparin affinity, our MD simulations suggest a
non-specific, surface-mediated binding interaction between
YKL-40 and the extensively sulfated heparin oligomer (10, 11).
Although the unsulfated variant, heparan sulfate, did not visit
the heparin-binding site, chondroitin sulfate also attached to
the putative heparin-binding site in a similar fashion to heparin.
Given the chemical similarity of these glycosaminoglycans, i.e.
highly sulfated and negatively charged, we anticipate the
FIGURE 5. Snapshots from four independent MD simulations of heparin (white stick) binding to a putative heparin-binding site (blue surface) of YKL-40
(gray surface). The primary oligosaccharide binding site of YKL-40 is marked by an aromatic residue shown in salmon surface representation. Transparent
spheres illustrate the initial simulation positions of heparin. In two cases, a and b, the heparin ligand was initially bound in the primary YKL-40 binding site. In
both cases, the ligand was expelled from the primary binding site into solution and located the heparin-binding site through electrostatic interactions. Two
additional simulations, c and d, were initialized with the heparin ligand free in solution. Again, the ligands identified the YKL-40 heparin-binding domain
through charge-based interactions. The ligand did not specifically bind in a particular conformation. Rather, the ligand dynamically interacted with the
heparin-binding domain.
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XBBXBX motif may also routinely appear in chondroitin-bind-
ing proteins.
Polysaccharide Ligand Binding Affinity—Each of the three
polysaccharides maintaining contact with the primary binding
site of YKL-40, cellohexaose (or likely any glucose derivative),
chitohexaose, and hyaluronan, are feasible ligands. However,
free energy calculations suggest that hyaluronan may preferen-
tially bind with YKL-40 if chitin is not present in the human
body as a result of fungal infection. The absolute free energies of
binding cellohexaose, chitohexaose, and hyaluronan to YKL-40
were 12.6  3.7, 63.3  12.6, and 106.8  4.6 kJ/mol,
respectively. Repulsive, dispersive, and electrostatic compo-
nents of the free energy changes are tabulated in Table 1. Con-
vergence assessment of the free energy calculations has been
provided in supplemental Fig S3. We recently calculated the
free energy of solvation for chitohexaose as part of a study on
family 18 chitinases (68); this value has been used in our calcu-
lation of chitohexaose binding affinity to YKL-40 for computa-
tional efficiency. The methods used to calculate solvation free
energy of chitohexaose were identical to those described here.
Furthermore, the binding free energy of chitohexaose to
YKL-40 is in good agreement with that of homologous family 18
chitinases, despite mutation of the catalytic motif in the lectin.
Chitohexaose and cellohexaose are both neutral ligands but
display a significant difference in binding affinity to YKL-40.
Electrostatic interactions appear to be one of the more signifi-
cant contributors to the enhanced affinity of chitohexaose over
cellohexaose (Table 1). For cellohexaose, the change in the elec-
trostatic component of binding free energy was unfavorable
(20.1  2.7 kJ/mol), whereas the same component for chito-
hexaose was energetically favorable (31.4  8.2 kJ/mol). In
the case of hyaluronan, electrostatic interactions play an even
greater role in enhancing affinity of the ligand for YKL-40
(77.0  4.5 kJ/mol). This increasing electrostatic contribu-
tion is reflective of increasing number of electronegative atoms
in the side chains of carbohydrates as we go from cellopentaose
to chitohexaose to hyaluronan. We observe no significant dif-
ferences in cellohexaose, chitohexaose, or hyaluronan binding
to YKL-40 arising from Weeks-Chandler-Anderson (WCA)
dispersion and repulsion (Table 1). This is largely a function of
the molecular similarity of the pyranose rings comprising the
monomeric units of three oligosaccharides (Fig. 2). The pyra-
nose rings of carbohydrates bound in the active sites of glyco-
side hydrolases, and by extension the binding clefts of lectins,
form carbohydrate- stacking interactions with surrounding
aromatic residues along the clefts (69). In YKL-40, these stack-
ing interactions are formed in the 3 and 1 binding sites with
residues Trp31 and Trp352, respectively. Naturally, any polysac-
charide ligand capable of binding in the YKL-40 binding cleft
will likely exhibit a similarly favorable WCA binding free energy
component. In the following section, we expand upon the
molecular level interactions that contribute to polysaccharide
binding affinity in YKL-40.
Based on these results, it is unlikely that a cello-oligomer
would bind in the cleft of YKL-40 over a chito-oligomer, and
thus, although there is potential for YKL-40 to bind a cello-
oligomer or glucose, it would not be inhibitory. Hyaluronan, on
the other hand, likely competes with chito-oligomers in bind-
ing, which is due in large part to the electrostatic favorability of
the charged side chains of hyaluronan in the YKL-40 binding
cleft. Clinical data support hyaluronan as a biomarker for can-
cer prognosis and inflammation (32, 70), the same events in
which YKL-40 appears at elevated serum levels (5). To our
knowledge, there are no studies evaluating the co-existence of
YKL-40 and hyaluronan. The cell receptor protein CD44 has
been implicated in hyaluronan binding interactions and is
also involved in confounding scenarios, both aggravating and
improving inflammation (71). Sequence alignment of YKL-40
with the hyaluronan-binding domain of human CD44 (72),
using BLASTP 2.3.0 (73), shows no homology, further suggest-
ing that this YKL-40-hyaluronan binding is different from pre-
viously known hyaluronan-binding proteins (74).
Polysaccharide Binding Dynamics—YKL-40 is highly homo-
logous with carbohydrate-active enzymes found in glycoside
hydrolase family 18 (12, 75). Despite lacking catalytic ability, the
primary polysaccharide binding site of YKL-40 exhibits
remarkable similarity to these family 18 chitinases. As such, one
may reasonably expect that ligand binding within this family
will demonstrate similar trends, regardless of evolutionary ori-
gin. Indeed, we observe that chitohexaose, cellohexaose, and
hyaluronan binding in the primary binding site of YKL-40
follow a general pattern common to carbohydrate-active
enzymes. Namely, that ligand binding interactions are medi-
ated by carbohydrate- stacking interactions with aromatic
residues, and hydrogen bonding interactions are critical to
overall ligand affinity and stability. We investigate these trends
quantitatively through analysis of the MD simulation trajecto-
ries, including root mean square deviation (RMSD) of the pro-
tein, root mean square fluctuation (RMSF) of both the protein
and the ligands over the course of the simulation, hydrogen
bonding analysis, degree of solvation of the ligand, and interac-
tion energy of the ligand with the protein.
Cellohexaose, chitohexaose, and hyaluronan binding in the
primary YKL-40 binding site did not adversely affect protein
dynamics. In each case, binding the polysaccharide ligand did
not significantly disturb the protein backbone (i.e. protein fold),
TABLE 1
Energetic components of the free energy of ligand binding to YKL-40
System Grepu Gdisp Gelec Grstr GTot Gb
kJ mol1 kJ mol1 kJ mol1 kJ mol1 kJ mol1 kJ mol1
YKL-40  Cellohexaose 379.5  3.8 382.3  2.1 306.6  2.2 1.1 310.5  3.6 12.6  3.7
Cellohexaose 316.2  1.8 287.4  1.3 326.7  1.6 0 297.9  2.8
YKL-40  Chitohexaose 535.9  11.7 538.9  4.2 407.7  7.5 5.5 416.2  11.2 63.3  12.6
Chitohexaosea 329.6  4.5 306.2  3.0 376.3  3.4 0 352.9  5.9
YKL-40  Hyaluronan 438.1  2.8 439.5  1.5 1395.9  4.2 1.3 1398.6  4.3 106.8  4.6
Hyaluronan 333.1  1.4 306.0  1.3 1318.9  1.5 0 1291.8  2.5
a Hamre et al. (68).
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and the ligand remained relatively unperturbed over the course
of the simulation. The relatively consistent RMSD of the pro-
tein backbones suggests that the simulations reached a local
equilibrium ( supplemental Fig. S4a). As with the RMSD calcu-
lation, the RMSF of the protein backbone suggests that the
binding of polysaccharides does little to disturb the overall pro-
tein conformation (supplemental Fig. S4b). Additionally, we
did not observe significant conformational changes in the car-
bohydrate-binding site of YKL-40 before or after ligand binding
(supplemental Fig. S5). More details of protein dynamics and
conformational changes have been provided in the supplemen-
tal text.
The RMSF of the ligand, averaged over 250 ns as a function of
binding site, provides a measure of relative ligand stability.
Error was estimated by block averaging over 2.5-ns blocks.
Ligand stability over the course of the simulation suggests hya-
luronan is as stable, if not more so, as chitohexaose in the pri-
mary binding site (Fig. 6a); however, cellohexaose appears to be
more stable relative to the two other ligands at the ends of the
binding cleft. This latter finding is a function of the length of the
side chains attached to the pyranose rings of each of the ligands.
Of the three carbohydrates, the cello-oligomer has the shortest
side chains, and thus, the ligand fluctuates less because it does
not need to rearrange as significantly to induce binding. As
shown above, this does not necessarily correspond to the most
thermodynamically preferential ligand, and lower RMSF could
also be interpreted hypothetically as loss of translational and
conformational freedom, resulting in unfavorable entropic
contribution.
The hydrogen-bonding partners of chitohexaose, cello-
hexaose, and hyaluronan are quite different, largely as a result
of the conformational change of hyaluronan (supplemental
Table S4). Defining a hydrogen bond as a polar atom within 3.4
Å and 60° of a donor, we identified the formation of donor-
acceptor pairs and percent occupancy of these hydrogen bonds
between the protein and each carbohydrate moiety over the
course of the 250-ns MD simulations (supplemental Table S4).
As described above, hyaluronan formed a sharp V shape in the
polysaccharide binding cleft, which minimized steric hindrance
and, in turn, modified accessible hydrogen bonding partners
relative to chito- and cellohexaose. Hydrogen bonds at the 1
site, between glucuronic acid and Asp207, Arg263, and Tyr141,
stabilized the hyaluronan conformation (supplemental Table
S4). In the 1 subsite, chitohexaose primarily hydrogen bonds
with the side chain of Tyr206 and the main chain of Trp99. In the
cases of both cellohexaose and hyaluronan, the interaction with
Tyr206 was abolished and instead supplemented by Trp99 alone.
In the 2 subsite, the oxygen of the chitohexaose acetyl forms a
long-lived hydrogen bond with the indole nitrogen of the bur-
ied Trp352; neither hyaluronan nor cellohexaose interact with
the 2 site through this tryptophan. Rather, Trp31, which
stacks with the pyranose in the 3 subsite, acts as a hydrogen
donor to the 2 subsite glucuronic acid side chain of hyaluro-
nan. In the case of cellohexaose, the main chain of a solvent-
exposed asparagine, Asn100, almost exclusively mediates
hydrogen bonding in the 2 site. The 2, 3, and 4 binding
subsites exhibit less frequent hydrogen bonding between the
ligand and the protein, and there is little consistency in bonding
partners across ligands. Certainly, these variations will manifest
in enthalpic contributions to ligand binding, because even a
single hydrogen bond may account for 4 –29 kJ/mol of binding
free energy in biological systems (76, 77); such is likely the case
for cellohexaose and chitohexaose binding to YKL-40, where
the latter exhibits both greater hydrogen bonding capability
and a more favorable binding free energy.
Key aromatic residues, Trp31, Trp99, and Trp352, play a sig-
nificant role in binding all three oligosaccharides. Notably,
these tryptophans are conserved in other lectins, including
mammary gland protein (MGP-40) and mammalian lectin Ym1
(20, 78). According to previous structural studies, these aro-
matic residues form hydrophobic stacking interactions with
pyranose moieties at the 3, 1, and 1 binding subsites,
respectively (11). As mentioned above, this carbohydrate-
stacking was observed across the three polysaccharide ligands
FIGURE 6. a, RMSF of the polysaccharide ligands on a per-binding-subsite
basis. The error bars were calculated using block averaging over 2.5 ns. b,
average number of water molecules within 3.5 Å of each ligand monomer.
The error bars represent one standard deviation.
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as a result of the chemically similar carbohydrate “backbone” of
pyranose rings. However, at the 1 site of hyaluronan, the
stacking interaction with Trp99 was not maintained. Instead,
prominent hydrogen bonding forces the 1 pyranose ring in an
orientation that is perpendicular to aromatic Trp99 (supple-
mental Fig. S6). Nevertheless, the similarity in WCA contribu-
tions to binding free energy for all three polysaccharides sug-
gests that this 1 site stacking interaction weakly contributes
to the overall binding free energy.
The degree to which the binding cleft of YKL-40 was acces-
sible to water molecules did not change significantly with the
bound polysaccharide. The degree of ligand solvation was
determined by calculating the average number of water mole-
cules within 3.5 Å of a given pyranose ring over the course of the
simulations (Fig. 6b); error is given as one standard deviation.
Chitohexaose and cellohexaose display similar degrees of sol-
vation across the length of the cleft. Hyaluronan allows a mod-
erate increase in degree of solvation of the cleft by comparison
to chitohexaose, across the 3 and 1 subsites, where its sharp
V shape again contributes to variation in behavior. Given the
similarity in solvent accessibility within the binding cleft
regardless of ligand, it is unlikely that entropic contributions
from solvation play a role in the observed differences in ligand
binding free energy.
Protein-Protein Binding in YKL-40 —Based on biochemical
characterization, it is clear that YKL-40 functionally interacts
with collagen. For example, Bigg et al. (9) uncovered the ability
of YKL-40 to specifically bind types I, II, and III collagen fibers,
and Iwata et al. (79) recently discovered that YKL-40 secreted
by adipose tissue inhibits degradation of type I collagen by
matrix metalloproteinase-1 and further stimulates the rate of
type I collagen formation. However, a lack of structural evi-
dence has precluded development of an understanding of the
molecular nature of these interactions. Using molecular dock-
ing, MD simulation, and free energy calculations, we describe
interactions of four collagen-like peptides with two putative
protein-binding sites along the surface of YKL-40. The selec-
tion of model peptides, as well as multiple binding sites, encom-
passes as many potential binding modes as feasible to describe
protein-protein binding dynamics and relative affinity of
YKL-40 for collagen.
Ligand Binding Dynamics and Comparison of Model Col-
lagen-like Peptides—Dynamics of the collagen-like peptide
ligands varies with both binding site and the pitch of the triple
helix. Root mean square deviation illustrates the relative stabil-
ity of each collagen peptide in each of the two binding sites, A
and B (supplemental Fig. S7). Although the molecular docking
results in very close contact between collagen and YKL-40 (Fig.
4), such that collagen appears to be almost buried in the pri-
mary carbohydrate-binding site of YKL-40, minimization and
MD simulation results in the slight rise and shift in the position
of collagen for every model at binding site A. Each of the four
ligands maintains association with the binding site A over the
course of 250 ns, although with slightly different protein-pro-
tein contacts with YKL-40 (Fig. 7). Native 1CAG, 1BKV, and
1Q7D attained relative stability in a position not significantly
different from the initial docked position, but the 1CAG pep-
tide (supplemental Movie S3), with disrupted helical content
resulting from the glycine to alanine mutation, required an adjust-
ment in pitch before associating with YKL-40. This relative change
in position is shown in the RMSD of the peptides during first
50–100 ns before stabilization (supplemental Fig. S7a). Binding
site B accommodates helical pitches of 7/2 collagen peptides,
because native 1CAG and 1Q7D associated with YKL-40 with
very little change in orientation relative to the initial docked
positions. The 1CAG ligand was expelled from binding site B, as
was the somewhat imperfect 10/3-pitched 1BKV peptide. This
suggests that YKL-40 may avoid physiological interactions with
certain collagen fibril domains, especially those having imper-
fect helical pitches. The integrin-binding collagen-like peptide
1Q7D demonstrated the greatest stability among collagen pep-
tides in both binding sites (supplemental Fig. S7) and formed
more native contacts with YKL-40 than the other three collagen
peptides at binding site A (Fig. 7). We anticipate that the
GFOGER motif plays substantial role in mediating the interac-
tion of this collagen peptide with YKL-40.
FIGURE 7. Native contact analysis of each collagen-like peptide model binding to YKL-40 at site A. The color scale represents the normalized frequency
(i.e. fractional percentage of frames in which the contact was formed) of the respective YKL-40 residue as a native contact. A native contact was defined as any
time a collagen residue was within 12 Å of a YKL-40 residue, where distance was defined by center of geometry of a given residue. Only frames from the last 100
ns of simulation, following a period of equilibration, were considered in this analysis.
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Examining the number of native contacts between each col-
lagen peptide and binding site A of YKL-40 reveals several com-
mon interaction sites mediate collagen binding and helps nar-
row down key regions of interest (Fig. 7). YKL-40 residues
69 –71, 98 –108, 205–215, and 230 –235 interact with all four
collagen peptides and likely contribute to binding affinity, as we
will discuss below. The region of YKL-40 between residues 179
and 189 associates with native 1CAG, 1BKV, and 1Q7D, but not
with the original 1CAG, as this peptide with relaxed symmetry
needed to adjust its position from docked conformation to sta-
bilize the interactions. The 1Q7D model formed the greatest
number of interactions with YKL-40 residues relative to the
other three models. Similar native contact analysis for binding
site B shows that even N-terminal and C-terminal residues of
YKL-40 are involved in collagen binding at binding site B (sup-
plemental Fig. S8). It shows that, unlike binding site A, there is
little difference in the number of interactions of model 1Q7D
and native 1CAG collagen peptide with the binding site B of
YKL-40.
To better understand the interactions collagen makes with
YKL-40, identified through the native contact analysis, we
calculated electrostatic and van der Waals interaction ener-
gies of each YKL-40 residue with each collagen peptide over
the 250-ns MD simulations (supplemental Table S5). Visual
inspection of the simulations reveals aromatic residues in the
binding sites, such as Trp212 and Trp99 in binding site A and
Phe49 in binding site B, were involved in aromatic-proline
stacking interactions with the collagen triple helices. Such
interactions are favorable, occurring because of both hydro-
phobic effects and interaction between the  aromatic face and
the polarized C-H bonds (80). This is illustrated in the van der
Waals component of the interaction energy, where at binding
site A, Trp69, Trp71, Trp99, Trp212, and Phe234 show substantial
favorable interaction with collagen peptides, although the con-
tribution varies with each collagen peptide (supplemental
Table S5). Additionally, acidic and basic residues of the integ-
rin-binding GFOGER motif from collagen-like peptide 1Q7D
form ionic interactions with the counter-ionic amino acids of
YKL-40, also known as salt bridges. Specifically, 1Q7D forms
three salt bridges at binding site A and one salt bridge at binding
site B (Fig. 8). At site A, Arg105, Asp207, and Arg263 of YKL-40
interact with Glu(a11), Arg(c12), and Glu(c11) of 1Q7D,
respectively, where the a, b, or c in the parentheses corresponds
to one of the three strands of the collagen model. Notably,
Glu(a11), Arg(c12), and Glu(c11) belong to the GFOGER integ-
rin-binding motif. At site B, Lys23 of YKL-40 forms a salt bridge
with Glu(a11) of 1Q7D. As anticipated, the GFOGER motif
played a substantial role in the interaction of this collagen pep-
tide with YKL-40, but its role was different from that of the
integrin binding mechanism, which further involves coordina-
tion of a metal ion (42). Nevertheless, salt bridges and hydro-
phobic contacts are very important in both cases, significantly
contributing to the electrostatic component of the binding
affinity of this collagen peptide relative to collagen peptides
lacking acidic or basic amino acids (e.g. native 1CAG) (supple-
mental Table S5). The hydroxyl oxygens of hydroxyprolines
from 1CAG and native 1CAG appear to be involved in ionic
interactions with acidic YKL-40 residues (favorable electro-
static interaction energies; supplemental Table S5), although as
a result of hydrogen bonding rather than salt bridge formation.
We note that the interaction energies of YKL-40 residues with
residues of each collagen model peptide are not conserved as a
result of differences in the collagen sequences, particularly in
the middle regions consisting of different imino-triplets.
From MD simulation, we observe substantial hydrogen
bonding between the collagen peptides and YKL-40 across the
length of each binding site, which contributes to overall stabil-
ity and binding affinity. The hydrogen bonding analysis for the
collagen-YKL-40 systems was performed as described above for
the polysaccharide ligands; pairs exhibiting greater than 10%
occupancy over the simulation are reported individually in
supplemental Table S6. The YKL-40 residues responsible for
FIGURE 8. Collagen binding with YKL-40. a, salt bridges formed between
the 1Q7D collagen peptide (green cartoon) and binding site A (gray surface). b,
salt bridge interactions of the 1Q7D collagen peptide (cyan cartoon) with
binding site B (gray surface). c, binding free energy obtained from umbrella
sampling MD simulations of the YKL-40-collagen peptide systems, inter-
preted as negative of PMF to decouple the partners. The collagen peptides in
question are 1Q7D (at both sites) and 1CAG (at site A only). The free energy is
shown as a function of normalized reaction coordinate, where the reaction
coordinate is fraction of native contacts.
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hydrogen bonding are not consistent across each collagen
model (supplemental Table S6). In general, Glu70, Trp99,
Asn100, Tyr141, Arg145, Ser179, Lys182, Thr184, Asp207, Arg213,
Phe218, Asp232, and Arg263 in binding site A form hydrogen
bonds with the peptides. Similarly at site B, Tyr22, Lys23, Asn87,
Asn89, Lys91, Lys377, and Asp378 are typically involved in hydro-
gen bonding. The variation in hydrogen bonding pairs between
YKL-40 and the collagen peptides is a natural extension of the
varying amino acids along the repeating Gly-Xaa-Yaa sequence;
there are many different potential donor and acceptor pairs in
each case. Hydroxyproline residues play a crucial role both as
donor and acceptor in most pairs, benefitting from the extra
hydroxyl group relative to proline. Although all the collagen
peptides maintain association with collagen-binding site A, the
hydrogen bonding characteristics are slightly different for each,
which will in turn lead to affinity differences. The relaxed heli-
cal pitch of the 1CAG peptide effectively disrupts hydrogen
bonding, and affinity for the ligand is lost at binding site B. The
1BKV peptide model with 10/3 symmetry was also unable to
remain associated with binding site B, suggesting that binding
site B may be more sensitive to helical pitch and prefers 7/2
symmetrical helices.
Collagen-like Peptide Binding Affinity—The relative binding
affinity of collagen-like peptides to YKL-40 was determined
from umbrella sampling MD simulations. Here, we report the
binding affinity of the 1Q7D collagen-like peptide, which is the
integrin binding peptide with an overall 7/2 helical pitch (41,
42), at both sites A and B. We have also calculated binding
affinity of native 1CAG at binding site A for comparison of
binding affinities of two different collagen peptides having dif-
ferent residue substitutions and helical pitches. Unfortunately,
in case of umbrella sampling for the native 1CAG peptide at site
B, we were unable to obtain statistically reliable results, and
thus, we will not discuss findings relative to the affinity of this
model.
The umbrella sampling MD simulations of the 1Q7D colla-
gen peptide at both sites A and B show that YKL-40 has similar
affinity for 1Q7D at both sites; however, the native 1CAG col-
lagen peptide appears to bind with a lower affinity than 1Q7D at
binding site A (Fig. 8c). We note that the last umbrella sampling
window in case 1Q7D at binding site A shows a sudden, sharp
increase in the potential of mean force (PMF), which is an arti-
fact of the use of native contacts as an umbrella sampling reac-
tion coordinate. As the standard C termini of three strands of
collagen helix are negatively charged, they are attracted to the
nearby, highly positively charged surface of heparin-binding
site. As a result, the final window of the PMF overestimates the
work to remove the 1Q7D peptide from binding site A exclu-
sively (Fig. 8). Removing this latter window from the calcula-
tion, the free energy of binding 1Q7D is 40.8  4.7 kJ/mol in
site A and 42.9  5.0 kJ/mol in site B. The free energy of
binding native 1CAG in site A is 22.0  3.4 kJ/mol. The rel-
atively low statistical uncertainty at each window along the
potential of mean force suggests sampling of the system was
sufficient, providing a meaningful estimate of binding affinity.
The potential of mean force determined from umbrella sam-
pling MD simulations determines the amount of work required
to pull the collagen ligand from the binding site. Because free
energy is a state function, the difference between the beginning
and end state is the binding affinity, regardless of the path
taken, as reported above. The path can provide information as
to barriers to unbinding; however, the collagen peptides are
readily removed from the binding sites along a relatively
smooth path. This suggests there is little conformational rear-
rangement required of YKL-40 in the release of the collagen
ligand. The difference between affinity for 1Q7D and native
1CAG at binding site A is reflected in the total hydrogen bond-
ing occupancy in those two cases (supplemental Table S6).
Notably, the binding free energies of collagen to YKL-40 are
approximately half that of the tighter binding polysaccharide
ligands. This suggests that YKL-40 will bind both hyaluronan
and chito-oligomers over collagen in the presence of all three.
This does not rule out collagen as a physiological ligand but
strongly supports hyaluronan as a preferred physiological
ligand of YKL-40.
Conclusions—We constructed polysaccharide-bound YKL-40
models and collagen peptide-bound models to understand the
molecular level interactions of the protein with potential phys-
iological ligands. MD simulations, as well as free energy calcu-
lations, overwhelmingly suggest that polysaccharide ligands, in
particular chito-oligomers and hyaluronan, are preferential
physiological ligands of YKL-40. However, YKL-40 does appear
to bind collagen peptides at two locations along the surface of
the molecule. This demonstrates diversity of function of
YKL-40 and may potentially be related to the promotion or
inhibition of collagen fibril formation, because one could easily
imagine that YKL-40 mediates interaction between the triple
helix fibers, potentially disrupting the natural matrix. Further
structural studies of YKL-40collagen complexes are certainly
warranted and would be invaluable in our understanding of
YKL-40 protein-protein interactions.
The apparent difference in binding affinity of YKL-40 for the
polysaccharide ligands and collagens is related to the ability of
the smaller ligands to penetrate the primary binding cleft.
These ligands are able to form longer-lived hydrogen bonds
deeper in the hydrophobic interior of the protein. Additionally,
electrostatic interactions play a key role in ligand recognition
and affinity to YKL-40. Improper alignment of the large,
charged side chains of heparan sulfate, heparin, and chondroi-
tin sulfate with the residues lining the YKL-40 cleft prohibits
these ligands from binding in the primary binding cleft. How-
ever, the smaller, negatively charged side chain of hyaluronan
interacts favorably in the primary binding cleft and contributes
significantly to the affinity of this molecule. Additionally, we
confirmed the non-specific interaction of heparin with the
putative heparin-binding domain suggested from previous
structural studies. The charged side chains repeatedly and
spontaneously interact with charged residues at this secondary
surface-binding site.
Overall, our findings indicate that YKL-40 may interact with
several ligands in vivo, including both polysaccharides and col-
lagen. We suggest that hyaluronan is a preferential physiologi-
cal ligand of YKL-40, which may explain the pervasive associa-
tion of YKL-40 with the physical maladies in which hyaluronan
has been associated (2, 5, 81, 82). These findings not only iden-
tify physiological ligands of YKL-40, they enable future efforts
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to rationally guide design of YKL-40 inhibitors, the design of
which is invaluable in the control of inflammation-based disor-
ders and possibly several types of cancer.
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Detailed Methods 
Molecular Dynamics (MD) Simulation 
Protonation states of all the titratable residues were determined according to the corresponding 
pKa values calculated by the H++ web server (1). The protein, structural waters, and ligands were 
constructed in a vacuum using CHARMM (2). The system was minimized for 1000 steps in vacuum 
using the Steepest Descent (SD) algorithm followed by another 1000 steps of minimization with the 
adopted basis Newton-Raphson (ABNR) algorithm. This procedure reduces the number of bad contacts 
prior to solvation of the solute. The polysaccharide systems were solvated in 100 Å × 100 Å × 100 Å 
cubic boxes, and the collagen-like peptide systems were solvated in 120 Å × 120 Å × 120 Å cubic boxes. 
Sodium or chloride ions were added to the solution to ensure overall charge neutrality. For neutral 
ligands, six chloride ions were required to neutralize the charge of YKL-40 titratable residues. The 
charged ligands, hyaluronan (-3), heparan sulfate (-12), and chondroitin sulfate (-9), required 3 chloride 
ions, 6 sodium ions, and 3 sodium ions for charge neutrality, respectively. After solvation, the systems 
were minimized again in the following sequence: 1000 steps of SD with the protein and ligand restrained, 
1000 steps of SD with only the protein restrained, and 2000 steps of SD and 2000 steps of ABNR with no 
harmonic restraints. Extensive minimization, up to 10000 steps of SD, was carried out for systems bound 
to highly sulfated polysaccharides and collagen. 
The solvated and minimized systems were then equilibrated prior to production MD simulations. 
The systems were heated from 100 K to 300 K in 50-K increments over 20 ps in the canonical ensemble. 
The system density was then equilibrated in the NPT ensemble at 300 K and 1 atm (101325 Pa) for 100 
ps. The Nosé-Hoover thermostat and barostat were used to control temperature and pressure in 
CHARMM (3,4).  
Production MD simulations of 250 ns were performed in the canonical ensemble at 300 K using 
NAMD (5). Temperature was controlled using Langevin thermostat (6). The SHAKE algorithm was used 
to fix the bond distances to all hydrogen atoms (7). Non-bonded interactions were truncated with a cutoff 
distance of 10 Å, a switching distance of 9 Å, and a non-bonded pair list distance of 12 Å. Long range 
electrostatics were described using the Particle Mesh Ewald method with a 6th order b-spline, a Gaussian 
distribution width of 0.320 Å, and a 1 Å grid spacing (8). The velocity Verlet multiple time-stepping 
integration scheme was used to evaluate non-bonded interactions every 1 time step, electrostatics every 3 
time steps, and 6 time steps between atom reassignments. All simulations used a 2-fs time step. The 
CHARMM36 force field with the CMAP correction (2,9,10) was used to describe YKL-40 and the 
collagen ligands. The parameters for hydroxyproline were determined using ParamChem, which 









program version 0.9.7 beta (11). The CMAP corrections for hydroxyproline were adopted simply based 
on the analogy between proline and hydroxyproline residues. The polysaccharides were described using 
the CHARMM36 carbohydrate force field (12-14). Water was modeled using the TIP3P force field 
(15,16). All simulations used explicit solvent. 
 A complete list of simulations and calculations performed to meet the objectives of this study is 
given in Table S1. As described in the manuscript, collagen docking calculations indicated two potential 
binding surfaces; for these cases, the description in Table S1 lists both site and ligand. The length of each 
MD simulation is also given, as not all simulation lengths were the same; several of the hypothesized 
ligands dissociated from the binding cleft, and the simulation was halted to conserve computational 
resources. The free energy calculations performed are also indicated. If a ligand did not remain in the 
binding cleft throughout the entirety of the MD simulation, a free energy calculation was not performed. 
 In addition to these protein-ligand or protein-protein complexes, oligo-saccharides and collagen 
models were solvated in water separately, without YKL-40. These ligand-only simulations were required 
as input to the free energy calculations. Several additional system configurations beyond those originally 
proposed were also developed, as described below, in order to study the effect of ligand position on 
conformational changes and to understand the statistical significance of observed interactions with the 
putative heparin-binding subsite. 
 
Table S1. Simulations and calculations performed in the investigation of the binding of polysaccharides 
and collagen ligands to YKL-40.  
 
Case No. System MD simulation 
Free Energy 
Calculation 
1 Apo YKL-40 250 ns -- 
2 YKL-40 + chitohexaose 250 ns FEP/λ-REMD 
3 YKL-40 + cellohexaose 250 ns FEP/λ-REMD 
4 YKL-40 + hyaluronan 250 ns FEP/λ-REMD 
5 a YKL-40 + heparin (fully sulfated)  50 ns -- 
6 YKL-40 + heparan sulfate (unsulfated) 50 ns -- 
7 YKL-40 + chondroitin sulfate 50 ns -- 
8 & 9 YKL-40 + collagen (1CAG) at site A & B 250 ns -- 
10 & 11 YKL-40 + collagen (native 1CAG) at site A & B 250 ns Umbrella Sampling 
12 & 13 YKL-40 + collagen (1BKV) at site A & B 250 ns -- 
14 & 15 YKL-40 + collagen (1Q7D) at site A & B 250 ns Umbrella Sampling 
a  Four YKL-40 + heparin systems were constructed: two with heparin initially in the primary 
polysaccharide binding cleft and two with heparin initially located in bulk solution (Figure 5). 
 Modeling of heparin in this study required development of new force-field parameters for 
GlcNAc (Figure S1) where the acetyl group was replaced by SO3-1. ParamChem was used to obtain an 
initial set of parameters (11,17). As the sulfamate anions were not explicitly supported, parameters 
obtained for –NHSO3 group by analogy required optimization. The Force Field Toolkit (ffTK) Plugin 
Version 1.0 in VMD, developed by Mayne et al. (18), was used to optimize the partial charges, bonds, 
angles, and dihedrals as described in the reference publication and provided examples. Parameters 
obtained using this approach are given in Table S2. 
 
Table S2. CHARMM-additive parameters for GlcNS optimized using the ffTK v.1.0 plugin in VMD. The 
atom labels are as illustrated in Figure S1.  
 
Bonds Kb b0 
C2 – N 271.158 1.464 
N – S1 332.175 1.823 
N – HN 440.214 1.029 
S1 – O2 540.346 1.452 
Angles Ktheta Theta0 
C1/C3 – C2 –N  91.721 112.507 
N – C2 –H2  114.884 111.824 
C2 – N – S1 124.591 117.44 
C2 – N – HN 79.624 107.895 
S1 – N – HN 74.629 129.979 
N – S1 – O2 152.857 109.282 
O2 – S1 – O7  103.66 105.957 
Dihedrals Kchi n Delta 
N – C2 – C1 – O5 0.2 3 0 
N – C2 – C3 – O3 0.2 3 0 
N – C2 – C1 – O1 0.2 3 0 
C4 – C3 – C2 – N 0.2 3 0 
N – C2 – C3 – H3 0.2 3 0 
N – C2 – C1 – H1 0.2 3 0 
C1/C3 – C2 – N – S1 1.12 3 180 
H2 – C2 – N – HN 0.527 3 180 
H2 – C2 – N – S1 2.994 3 0 
C2 – N – S1 – O2 1.048 3 180 
NH – N – S1 – O2 0.831 3 0 
C1/C3 – C2 – N – HN 1.575 1 0 
O4* – C1 – C2 – N  0.2 3 0 











Figure S1. Atom labels of N-sulfo-a-D-glucosamine structure used for optimization of missing 
force-field parameters. The only missing parameters were the ones around N-S1 bond as 










Free Energy Calculations 
FEP/ λ-REMD. For the free energy calculation, structures of the YKL-40·chitohexaose, YKL-
40·cellohexaose, and YKL-40·hyaluronan complexes were obtained from 25 ns snapshots of the MD 
simulations. A solvated polysaccharide ligand simulation was also generated to determine ΔG2 (Figure 
S2). For each of these systems, 20 consecutive 0.1-ns free energy perturbation calculations were 
performed with NAMD 2.9, using a replica exchange frequency of 1 exchange per 100 steps. The final 10 
calculations (1 ns) were averaged to determine the binding free energy. The simulations used a total of 
128 free energy perturbation replica windows: 72 dispersive, 24 repulsive, and 32 electrostatic. The 
oligosaccharide ligands were restrained in the ligand-binding pose using a harmonic restraint on the 
distance between the center of mass of the protein and the center of mass of the ligand. The harmonic 
restraint force constant was 41.84 kJ/mol/Å2. This restraint bias was removed from the free energy 
calculation according to the approach outlined by Deng and Roux (19). Multistate Bennett Acceptance 
Ratio (MBAR) was used to determine electrostatic, repulsive, and dispersive contributions to free energy 
(20). Standard deviation of the final 1 ns free energy values serves as the error estimate. All simulation 
parameters in the free energy calculations mimic those described in the MD simulations section. The 
progress towards the convergence of free energy calculations for cellohexaose, chitohexaose and 
hyaluronan systems are shown in Figure S3. 
 
 
Figure S2. Thermodynamic cycle used to determine ∆G with FEP/λ-REMD method. ‘solv’ refers to the solvated 










Figure S3. Convergence of ∆G over 20 consecutive 0.1-ns free energy perturbation calculations using the FEP/λ-
REMD method.  
 
Additional results and discussion 
RMSD and RMSF of protein in polysaccharide binding dynamics 
 The RMSD of the protein (FigureS4a) is a measure of deviation over the course of the simulation 
from the initial configuration, which was the first frame of the simulation following NPT density 
equilibration. The relatively consistent RMSD of the protein backbones suggests the simulations reached 
a local equilibrium. The magnitude of the RMSD change over 250 ns is small given the significant 
chemical differences in the three ligands examined, which indicates the primary YKL-40 binding site is 
forgiving of small charged side chains such as the carboxylate of hyaluronan. The RMSF fluctuation of 
the protein backbone similarly describes fluctuation of a given protein residue from the average position 
over the course of the entire simulation. As with the RMSD calculation, the RMSF of the protein 
backbone suggests the binding of chitohexaose and cellohexaose does little to disturb the overall protein 
conformation (Figure S4b). In the case of hyaluronan binding, we observe increased fluctuation in 
residues 178-189, 225-235, and 300-325 over that of cellohexaose and chitohexaose bound YKL-40. Both 
loops 225-235 and 300-325 are located away from the primary carbohydrate-binding site; the increase in 
flexibility in these loops appears to be related to solvent exposed polar residues sampling bulk solution 
and is likely unrelated to hyaluronan binding. Segment 178-189, comprising part of a β-sheet and a small 
α-helix just beneath the +1 and +2 binding sites, becomes increasingly mobile as its interaction with 
hyaluronan is lost in the formation of the sharp V-shape. Despite localized increases in backbone 
flexibility, the overall protein structure largely remains in the same initial conformation, as evidenced by 
the similarity in RMSD (Figure S4a). 
 
 
Figure S4. (a) Root-mean-square deviation over 250-ns MD simulations and (b) root-mean-square 
fluctuation of YKL-40 without a ligand (apo) and bound to chitohexaose, cellohexaose, and hyaluronan. 












Conformational changes in the YKL-40 binding site 
 Crystal structures of YKL-40 bound with chito-oligosaccharides suggest that YKL-40 undergoes 
a conformational change upon chitin ligand binding (21), contrary to suggestions that lectin binding sites, 
in general, are “pre-formed” to accommodate their natural substrates and undergo little change upon sugar 
binding (22). Houston et al. reported that the residues forming a loop (residues 209 to 213) near the 
primary YKL-40 binding cleft occupy an unusual conformation in apo YKL-40 when compared to the 
ligand bound YKL-40 structure, where Trp 212 lines the +2 and +3 subsites (21). However, a second 
structural investigation published concurrently did not observe a similar conformation change in either of 
two crystal structures (1NWR and 1NWS), where no ligand occupied either the +2 or +3 subsites (23). 
Additionally, the positioning of Trp99 at the +1 site in both apo structures of human YKL-40 (1HJX and 
1NWR) and the homologous MGP-40 (1LJY) differs from that of holo-YKL-40 and homologous 
mammalian lectin Ym1 (1E9L) (21,23-25), with the tryptophan blocking the binding cleft in the apo 
form. This conformational variation as a function of binding site occupancy has been proposed as a 
tryptophan-mediated gating mechanism for ligand binding in chitolectins (26).  
Based on MD simulations we did not observe data suggesting binding cleft rearrangement is 
important in polysaccharide binding to YKL-40. To investigate possible loop rearrangement upon ligand 
unbinding, the apo YKL-40 simulation was prepared by undocking the bound chitin oligomer. One can 
reasonably expect that over the course of a 250-ns MD simulation, the 5-amino acid residue loop would, 
at a minimum, sample a variety of conformations indicating flexibility in this region. However, in 
examining the trajectory of this loop with respect to its initial position, we did not observe the peptide 
loop returning to the unusual conformation in a single frame (Figure S5). This suggests that the 
crystallographic apo conformation may have resulted from serendipitous crystal packing interactions and 
may not represent a typical conformational behavior. Additionally, the phenomenon of tryptophan 
mediated gating, according to which one would expect the Trp99 to return to the “pinched” conformation 
of the apo state, was not observed. Though, we note the likelihood of observing that the latter behavior, 
i.e., returning to a “pinched” conformation, in an unbiased MD simulation is low and may require 
overcoming an energy barrier through enhanced sampling approaches.
 
 
Figure S5. Root mean square deviation of loop of residues 209 to 213 from the unusual configuration in apo YKL-
40 crystal structure during 250-ns MD simulation of apo YKL-40 prepared by removing the bound ligand from holo 




Figure S6. Hyaluronan in YKL-40 binding site at 0 ns (left) and at 250 ns (right) illustrating difference between V-











Figure S7. Root-mean-square deviation of collagen-like peptides over the course of 250-ns MD simulations at (a) 













Figure S8. Native contact analysis of each collagen-like peptide model binding to YKL-40 at site B. The color scale 
represents the normalized frequency (i.e., fractional percentage of frames in which the contact was formed) of the 
respective YKL-40 residue as a native contact. A native contact was defined as anytime a collagen residue was 
within 12 Å of a YKL-40 residue, where distance was defined by the center of geometry of a given residue. Only 





Table S3. Interaction energy between each YKL-40 residue and heparin oligosaccharide averaged over the 
trajectory after heparin non-specifically interacts with the putative surface-binding site. The table shows the data for 
residues with the most favorable total average interaction energies. All values are in kJ/mol.  
 
Residue VdW-Avg Elec-Avg Total Avg 
ARG145 -9.12 -468.99 -478.11 
LYS193 -9.89 -438.47 -448.35 
LYS155 -2.18 -330.12 -332.30 
ARG144 -8.85 -307.80 -316.65 
LYS147 -1.81 -262.19 -263.99 
HIS148 -13.41 -50.79 -64.20 
Table S4. Hydrogen bonding pairs from polysaccharide-bound molecular dynamics simulations. A hydrogen bond was defined as a polar atom having a donor-
acceptor distance of 3.4 Å and a 60° cutoff angle. Occupancy refers to the percent of the simulation during which the hydrogen bond was formed. Occupancies 




Cellohexaose Chitohexaose Hyaluronan 
Donor Acceptor Occupancy Donor Acceptor Occupancy Donor Acceptor Occupancy 
-4 
BGLC1-SC GLU70-SC 56.28% NAG1-SC GLU36-SC 9.32% LYS289-SC GCU1-SC 13.40% 
      LYS289-SC NAG1-MC 8.48% GCU1-SC TRP31-MC 12.55% 
-3 
TRP69-SC BGLC2-SC 53.32% NAG2-SC GLU290-SC 69.52% ASN100-SC NAG1-SC 35.71% 
BGLC2-SC GLU70-SC 34.76% ASN100-SC NAG2-MC 67.68% TRP69-SC NAG1-SC 9.76% 
ASN100-SC BGLC2-SC 21.80%           
-2 
ASN100-MC BGLC3-SC 87.40% TRP352-SC NAG3-MC 93.24% TRP31-SC GCU2-SC 41.46% 
     ASN100-MC NAG3-SC 66.00% ASN100-MC GCU2-SC 22.27% 
     NAG3-SC GLU290-SC 30.32% TRP99-MC GCU2-SC 16.03% 
     NAG3-SC ASN100-SC 13.44% ASN100-SC GCU2-SC 13.60% 
-1 
TRP99-MC BGLC4-SC 76.20% TYR206-SC NAG4-MC 75.16% TRP99-MC NAG2-MC 86.76% 
     TRP99-MC NAG4-SC 39.56%      
     TYR206-SC NAG4-SC 16.52%      
     NAG4-SC ASP207-SC 15.16%      
+1 
BGLC5-SC TYR141-SC 32.32% NAG5-MC ASP207-SC 74.08% GCU3-SC ASP207-SC 96.19% 
BGLC5-SC ASP207-SC 18.08% NAG5-SC TYR141-SC 17.00% ARG263-SC GCU3-SC 76.88% 
TYR141-SC BGLC5-SC 13.52% TYR141-SC NAG5-SC 15.04% TYR141-SC GCU3-SC 62.75% 
      ARG263-SC NAG5-MC 14.28%       
+2 
TYR141-SC BGLC6-SC 52.04% NAG6-MC TYR141-SC 45.68% TRP99-SC NAG3-SC 48.14% 
     TYR141-SC NAG6-SC 18.88%      
      TRP99-SC NAG6-SC 10.28%       
SC – Side chain; MC – Main chain; BGLC – β-D-glucose; NAG – N-acetyl-α-D-glucosamine; GCU – β-D-glucuronic acid. 
 
Table S5. Interaction energies of YKL-40 residues with collagen peptides. The values are reported in terms of 
average interaction energy between major YKL-40 residues and collagen as a whole. van der Waals and electrostatic 
contributions are also provided separately. Residues with total average interaction energy greater than -4.18 kJ/mol 
have not been reported unless relevant to discussion. Energies are given in kJ/mol. 





























ASP232 0.000 -27.814 -27.814 
THR184 -1.129 -16.381 -17.514 TRP99 -13.592 -7.553 -21.144 
LYS182 -0.723 -16.695 -17.418 TRP212 -15.666 0.351 -15.314 
TRP212 -13.667 -1.957 -15.624 VAL183 -9.899 -1.618 -11.517 
ASP207 -0.732 -14.353 -15.084 PHE234 -10.225 -0.084 -10.309 
TYR141 -4.437 -9.677 -14.118 ASN100 -5.290 -2.534 -7.825 
GLU70 0.042 -13.370 -13.328 GLU290 -0.694 -4.943 -5.637 
GLU290 -3.383 -8.109 -11.492 THR184 -2.835 -2.459 -5.294 
ARG145 0.138 -10.292 -10.154 GLN104 -2.196 -2.275 -4.466 
TYR34 -7.783 -0.815 -8.598 TYR141 -3.801 -0.385 -4.186 
ASN100 -6.821 -1.644 -8.464 ASP207 -0.661 -3.220 -3.881 
TRP99 -5.708 -2.308 -8.017       
PRO142 -0.381 -5.562 -5.943       
VAL183 -6.273 0.598 -5.675       
GLU36 -1.451 -3.919 -5.366         


























ASP207 -4.057 -59.811 -63.868 
TRP99 -13.081 -4.040 -17.121 PHE208 -5.294 -14.210 -19.501 
GLU290 -2.409 -9.656 -12.061 ALA180 -1.957 -17.447 -19.404 
ASN100 -8.243 -2.530 -10.773 TYR141 -5.445 -12.680 -18.125 
TRP69 -6.357 -3.191 -9.548 TRP99 -13.031 -4.563 -17.594 
TRP71 -8.975 -0.443 -9.418 HIS209 -7.373 -7.419 -14.792 
ALA211 -5.796 -2.802 -8.598 TRP212 -8.247 -4.015 -12.257 
TRP212 -6.620 -1.255 -7.871 LYS182 -1.577 -9.890 -11.467 
ASP207 -0.309 -5.591 -5.901 SER179 -1.752 -9.656 -11.408 
TYR34 -5.474 0.744 -4.730 GLU290 -4.985 -5.805 -10.790 
TRP31 -3.358 -0.506 -3.864 ARG213 -1.811 -8.811 -10.622 
      TYR206 -1.033 -8.607 -9.640 
      GLY210 -2.727 -6.888 -9.614 
      ALA211 -0.815 -7.891 -8.707 
      TYR34 -6.942 -1.246 -8.188 
      GLU36 -1.853 -4.328 -6.181 
      VAL183 -5.943 0.146 -5.796 
      ASN100 -3.960 -1.455 -5.420 
        TRP31 -4.583 -0.372 -4.951 





























ASN89 -11.965 -26.439 -38.399 
TYR22 -4.788 -46.654 -51.443 LYS377 -7.122 -26.133 -33.255 
LYS91 0.046 -38.608 -38.562 ASP378 -5.119 -15.812 -20.927 
PHE49 -15.130 -1.878 -17.004 ALA381 -9.368 -3.538 -12.906 
ASP367 -0.259 -16.097 -16.360 GLN166 -6.411 -4.199 -10.606 
LYS377 -5.361 -9.142 -14.507 THR52 -8.163 -2.308 -10.472 
THR52 -3.178 -10.120 -13.295 GLN171 -6.382 -3.015 -9.397 
ASP47 -0.949 -8.310 -9.263 PHE49 -7.365 -0.912 -8.280 
LYS253 -1.171 -6.821 -7.992 TYR22 -4.412 -2.639 -7.051 
ASN89 -6.917 -0.719 -7.632 LYS91 -3.726 -2.881 -6.612 
ASP378 -0.941 -5.717 -6.658 LEU50 -2.831 -2.865 -5.696 
ALA381 -5.228 0.322 -4.910 HIS53 -2.798 -2.262 -5.060 
        ASP199 -0.544 -3.680 -4.224 
Table S6. Hydrogen bonding pairs between YKL-40 and collagen model peptides at binding site A, including 
percentage occupancy, over 250-ns MD simulations. A hydrogen bond was considered to be a polar atom having a 
donor-acceptor distance of 3.4 Å and a 60° cutoff angle. Occupancies above 100% mean that the same pair was 
involved in more than one type of hydrogen bond. 
1Q7D - binding site A Native 1CAG - binding site A 
Donor Acceptor Occupancy Donor Acceptor Occupancy 
ARG263-SC GLU11-SC 164.84% ARG213-SC HYP8-SC 79.68% 
ARG12-SC ASP207-SC 126.36% HYP8-SC ASP232-SC 76.56% 
ARG12-SC THR184-SC 51.96% GLN104-MC HYP14-SC 19.60% 
ARG12-SC ALA291-MC 26.76% SER103-MC HYP14-SC 16.24% 
HYP9-SC GLU290-SC 25.56% ARG233-SC HYP2-SC 13.44% 
HYP6-SC GLU70-SC 18.80% HYP17-SC ASN100-SC 10.32% 
TYR141-SC GLU11-SC 17.28% other pairs 123.68% 
ASN100-SC HYP9-SC 14.56%   
 
  
ARG12-SC SER179-SC 13.44%   
 
  
HYP6-SC TYR34-MC 13.24%   
 
  
ARG12-SC ASP207-MC 12.04%   
 
  
other pairs 100.20%   
 
  
Total 585.04% Total 339.52% 
  
1CAG - binding site A 1BKV - binding site A 
Donor Acceptor Occupancy Donor Acceptor Occupancy 
HYP20-SC GLU70-SC 75.72% TRP99-SC ALA17-MC 64.92% 
ASN100-SC HYP17-MC 35.84% ARG14-MC PHE218-MC 56.88% 
GLY214-MC HYP5-MC 29.24% ARG11-SC SER179-SC 54.08% 
ARG213-SC HYP5-SC 26.20% LYS182-SC THR8-SC 45.60% 
HYP14-SC ALA291-MC 17.80% ARG11-SC TYR141-SC 42.56% 
GLY214-MC GLY6-MC 11.00% ARG11-SC ALA180-MC 40.04% 
other pairs 112.08% ARG11-MC THR184-SC 33.00% 
  
 
  ARG11-SC ASP207-MC 28.64% 
  
 
  ARG11-SC ASP207-SC 21.56% 
  
 
  ARG213-SC THR11-MC 20.24% 
  
 
  ARG14-SC GLY210-MC 15.92% 
  
 
  ARG11-SC TYR206-MC 13.72% 
  
 
  TYR141-SC GLY12-MC 13.04% 
  
 
  TRP212-SC GLY12-MC 12.76% 
  
 
  ARG14-SC ALA211-MC 11.04% 
  
 
  other pairs 80.28% 
Total 307.88% Total 554.28% 
  
1Q7D - binding site B Native 1CAG - binding site B 
Donor Acceptor Occupancy Donor Acceptor Occupancy 
LYS23-SC GLU11-SC 120.84% ASN89-SC GLY18-MC 94.68% 
ASN87-SC HYP6-SC 61.20% HYP17-SC ASN89-MC 84.72% 
ASN89-SC HYP6-MC 55.32% LYS377-SC HYP20-MC 59.92% 
LYS91-SC HYP9-SC 23.80% ASN89-SC HYP17-MC 47.84% 
LYS377-SC HYP3-SC 21.12% HYP23-SC ASP378-SC 32.80% 
LYS91-SC GLU11-SC 18.68% LYS377-SC GLY21-MC 30.20% 
LYS377-SC GLY1-MC 16.52% GLN166-SC HYP8-MC 18.40% 
TYR22-MC GLU11-SC 15.48% HYP20-SC ALA381-MC 16.92% 
GLN171-SC HYP15-SC 11.76% ASN87-SC HYP20-SC 15.68% 
GLN171-SC HYP18-SC 11.16% HYP11-SC LYS169-MC 15.28% 
THR52-SC GLU11-SC 10.00% GLN171-SC HYP11-MC 15.04% 
other pairs 129.24% LYS91-SC HYP17-SC 12.80% 
  
 
  other pairs 98.36% 
Total 495.12% Total 542.64% 
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